Managing drug interactions in the treatment of HIV-related tuberculosis
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

For very narrow results

When looking for a specific result

Best used for discovery & interchangable words

Recommended to be used in conjunction with other fields

Dates

to

Document Data
Library
People
Clear All
Clear All

For additional assistance using the Custom Query please check out our Help Page

i

Superseded


This Document Has Been Replaced By: Managing drug interactions in the treatment of HIV-related tuberculosis

Managing drug interactions in the treatment of HIV-related tuberculosis

Filetype[PDF-228.99 KB]


English
Details Related Documents You May Also Like

Details:

  • Corporate Authors:
    National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (U.S.), Division of Tuberculosis Elimination.
  • Description:
    Worldwide, tuberculosis is the most common opportunistic infection among people with HIV infection. In addition to its frequency, tuberculosis is also associated with substantial morbidity and mortality. Despite the complexities of treating two infections requiring multidrug therapy at the same time, antiretroviral therapy can be life-saving among patients with tuberculosis and advanced HIV disease. Observational studies in a variety of settings have shown that use of antiretroviral therapy during tuberculosis treatment results in marked decreases in the risk of death or other opportunistic infections among persons with tuberculosis and advanced HIV disease . Concomitant use of treatment for tuberculosis and antiretroviral therapy is complicated by the adherence challenge of polypharmacy, overlapping side effect profi es of antituberculosis drugs and antiretroviral drugs, immune reconstitution inflammatory syndrome, and drug-drug interactions. The key interactions, and the focus of this document, are those between the rifamycin antibiotics and four classes of antiretroviral drugs: protease inhibitors, non-nucleoside reverse-transcriptase inhibitors [NNRTI], CCR5-receptor antagonists, and integrase inhibitors. Only two of the currently available antiretroviral drug classes, the nucleoside analogues (other than zidovudine) and enfuvirtide (a parenteral entry inhibitor) do not have significant interactions with the rifamycins. The purpose of this summary is to provide the clinician with updated recommendations for managing the drug-drug interactions that occur when using antiretroviral therapy during tuberculosis treatment. Changes from previous versions of these guidelines include: an effort to obtain and summarize the clinical experience of using specific antiretroviral regimens during tuberculosis treatment (not just pharmacokinetic data), a table summarizing the clinical experience with key antiretroviral regimens and providing recommended regimens (Table 1), and sections on treatment for special populations (young children, pregnant women, patients with drug-resistant tuberculosis). We include drug-drug interaction data for antiretroviral drugs that have been approved or are currently available through expanded access programs in the United States; these recommendations will be updated as additional antiretroviral drugs progress become available.- p. 5
  • Content Notes:
    Produced by the Division of Tuberculosis Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention.

    Includes bibliographical references (p. 12-14).

    CDC. Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis [online]. 2007. Available from URL: http://www.cdc.gov/tb/TB_HIV_Drugs/default.htm

    Text in PDF format (228.99 KB , 20 p.).

  • Subjects:
  • Document Type:
    Pamphlet (or booklet)
  • Place as Subject:
    United States
  • Collection(s):
  • Main Document Checksum:
  • Download URL:
  • File Type:

Supporting Files

  • No Additional Files
More +

Related Documents

This document has replaced (most recent first):
  1. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus principles of therapy and revised recommendations
    Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus; principles of therapy and revised recommendations
    Filetype[PDF - 743.08 KB]
    Personal Author:
    Villarino, M. Elsa
    October 30, 1998 | MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports ; v. 47, no. 20
    Description:
    "These guidelines update previous CDC recommendations for the diagnosis, treatment, and prevention of tuberculosis (TB) among adults and children coin...
    Status:
    superseded
    File Type:
    Filetype[PDF - 743.08 KB]
    File Type:
    Filetype[PDF - 743.08 KB]
  2. Guidelines for preventing the transmission of tuberculosis in healthcare settings with special focus on HIVrelated issues
    Guidelines for preventing the transmission of tuberculosis in health-care settings, with special focus on HIV-related issues
    Filetype[PDF - 108.19 KB]
    Personal Author:
    Castro, Kenneth G. ;
    Dooley, Samuel W.
    ...
    December 7, 1990 | MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports ; v. 39, no. RR-17
    Description:
    "The transmission of tuberculosis is a recognized risk in health-care settings. Several recent outbreaks of tuberculosis in health-care settings, incl...
    Status:
    superseded
    File Type:
    Filetype[PDF - 108.19 KB]
    File Type:
    Filetype[PDF - 108.19 KB]

You May Also Like

Checkout today's featured content at stacks.cdc.gov